The Wall Street Journal (online registration required): A Food and Drug Administration advisory committee voted 11-0 against the approval of a Novartis AG drug for acute heart failure, but the company said it plans to persist in developing the drug.
Novartis said it had presented its best evidence gathered thus far, but it plans to continue with the drug serelaxin because of the "urgent patient need." Drugs for acute heart failure have generally been very disappointing.
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Nowi360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Now